Users Coming Off Weight-Loss Medications Put On Weight at a Quadrupled Rate Than Those on Conventional Diets

A recent study suggests that patients who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who stop traditional diet and exercise programs.

Findings released in a major medical journal points out that while overweight people can lose substantial amounts of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month once they quit.

"Individuals buying these drugs should be informed of the risk of rapid weight regain when the treatment ends," warns lead investigator Dr. Susan Jebb.

Such speed of recovery suggests a reversion to starting mass in about a year and a half.

Comparing Treatments

The research, which examined 37 of studies involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with other pills.

The team emphasize that individuals who shed pounds through dieting usually have a slower weight regain—approximately 0.1 kg a month—post-intervention.

Explaining the Rapid Regain

Nutrition scientists believe the mechanism of the drugs is key to understanding the accelerated regain.

These medications imitate a body's own chemical called glucagon-like peptide-1, which controls appetite.

"Sustained high doses of the hormone levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.

"Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making overeating much more probable."

A Lifelong Issue?

The NHS suggest the injections for people with weight-linked medical conditions, alongside recommended lifestyle changes.

Professionals argue that, given the significant potential of weight regain, the treatment is often long-term.

This perspective is reinforced by pharmaceutical companies, who state that the findings "emphasize the persistent character of obesity," comparing it to managing conditions like diabetes.

Patient Testimonies

People who have discontinued the jabs explain a sudden resurgence of appetite.

"I experienced a switch flipping and I was suddenly starving," recalled one woman.

This challenge is exacerbated if users have not developed lasting lifestyle or habit changes during therapy.

Widespread Interest

Recent estimates indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.

• Adoption is higher among women than men.
• The 40s and 50s demographic shows the highest level of interest.
• A large proportion obtain the medications through private prescriptions rather than public health services.

Finally, clinicians stress that while these medications are potent tools for shedding pounds, they are not a permanent fix and long-term success likely depends on ongoing lifestyle changes.